AACR: Exosome-Based miRNA Assay Can Detect Pancreatic Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, April 8, 2024 -- An exosome-based liquid biopsy assay can distinguish patients with pancreatic ductal adenocarcinoma (PDAC) from healthy donors (HDs), according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
Caiming Xu, M.D., Ph.D., from the Beckman Research Institute of The City of Hope in Monrovia, California, and colleagues performed a real-time quantitative polymerase chain reaction-based assay using the plasma biospecimen from four prospective cohorts. The performance of the microRNA (miRNA) signature was also examined in conjunction with plasma CA19-9 for detecting early-stage PDAC.
The researchers found that two distinct panels of cell-free-miRNAs and exosomal-miRNAs robustly distinguished patients with PDAC from HDs in the training cohort from Japan. The signature resulting from combining these panels exhibited a notable ability to distinguish PDAC from HD with substantial accuracy in the training cohort (area under the curve [AUC], 0.98). This signature was successfully validated and evaluated in three independent cohorts from the United States, Korea, and China (AUCs, 0.93, 0.91, and 0.88, respectively). When the signature was combined with CA19-9 in the U.S. cohort, the overall diagnostic performance of this liquid biopsy assay significantly improved early detection of PDAC (AUC, 0.97; sensitivity and specificity, 0.95 and 0.96, respectively).
"We have established an exosome-based signature that combines exosomal microRNAs and cell-free DNA to robustly identify patients with early-stage pancreatic cancer," Xu said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Researchers Compare Race-Based, Race-Neutral Lung Function Equations
TUESDAY, May 21, 2024 -- The use of race-based and race-neutral equations for lung-function testing generate similarly accurate predictions of respiratory outcomes, but differ in...
Survival Benefit for Cancer Trial Participants Does Not Persist in Adjusted Analyses
TUESDAY, May 21, 2024 -- In studies using designs addressing sources of bias and confounding, there is no evidence of a survival benefit for cancer trial participants, according...
Genital Talc Use Positively Linked to Ovarian Cancer
TUESDAY, May 21, 2024 -- There is a positive association between use of intimate care products, including genital talc, and ovarian cancer, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.